FGEN - FibroGen, Inc.
| Previous Close | 39.39 |
| Open | 39.70 |
| Bid | 40.60 x 1000 |
| Ask | 43.50 x 800 |
| Day's Range | 39.50 - 41.44 |
| 52 Week Range | 38.52 - 68.55 |
| Volume | 618,151 |
| Avg. Volume | 532,233 |
| Market Cap | 3.456B |
| Beta (3Y Monthly) | 3.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.58 |
| Earnings Date | Nov 6, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 71.00 |
Markit•16 hours agoSee what the IHS Markit Score report has to say about FibroGen Inc.
Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold FGEN had net inflows of $1.75 billion over the last one-month.
- Thomson Reuters StreetEvents•5 days ago
Edited Transcript of FGEN earnings conference call or presentation 8-Nov-18 10:00pm GMT
Q3 2018 FibroGen Inc Earnings Call
- Zacks•5 days ago
FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of -42.86% and -37.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•5 days ago
FibroGen: 3Q Earnings Snapshot
The San Francisco-based company said it had a loss of 50 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•5 days ago
FibroGen Reports Third Quarter 2018 Financial Results
—Roxadustat New Drug Applications under Review in China and Japan——Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019——Conference Call Today.
Markit•8 days agoSee what the IHS Markit Score report has to say about FibroGen Inc.
Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $207 million over the last one-month into ETFs that hold FGEN are among the lowest of the last year and appear to be slowing.
- Simply Wall St.•8 days ago
What Kind Of Shareholder Appears On The FibroGen Inc’s (NASDAQ:FGEN) Shareholder Register?
If you want to know who really controls FibroGen Inc (NASDAQ:FGEN), then you’ll have to look at the makeup of its share registry. Insiders often own a large chunk of Read More...
- GlobeNewswire•11 days ago
FibroGen to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018
Conference Call and Audio Webcast Scheduled for 5:00 p.m. ET (2:00 p.m. PT) SAN FRANCISCO, Nov. 02, 2018 -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today.
- GlobeNewswire•15 days ago
ASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
TOKYO and SAN FRANCISCO, Oct. 30, 2018 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas.
- GlobeNewswire•19 days ago
FibroGen Presents Results from Two Phase 3 Studies of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease Conducted in China at American Society of Nephrology Kidney Week 2018 Annual Meeting
FibroGen, Inc. (FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, and FibroGen China Medical Technology Development Co., Ltd. (FibroGen China), today announced the presentation of results from two Phase 3 multi-center, randomized, controlled clinical trials of roxadustat (FG-4592 or 罗沙司他1) for the treatment of anemia associated with chronic kidney disease (CKD) conducted in China at the American Society of Nephrology (ASN) Kidney Week 2018 annual meeting in San Diego, California. Roxadustat is a first-in-class oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) in late-stage development for the treatment of anemia associated with CKD both in patients on dialysis and in patients not on dialysis.
- ACCESSWIRE•27 days ago
Today's Research Reports on Trending Tickers: Immunomedics and FibroGen
NEW YORK, NY / ACCESSWIRE / October 18, 2018 / Major U.S. equities finished moderately lower on Wednesday with the Dow Jones dropping over 300 points after minutes from the Federal Reserve September’s ...
- GlobeNewswire•28 days ago
FibroGen Announces Four Clinical Presentations on Roxadustat at Upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting
Roxadustat Phase 3 Clinical Results in Late-Breaking Clinical Trial Posters and Oral Presentation SAN FRANCISCO, Oct. 16, 2018 -- FibroGen, Inc. (NASDAQ: FGEN), a leading.
- GlobeNewswire•29 days ago
Research Report Identifies The Habit Restaurants, Datawatch, SMART SAND INC, Independence Contract Drilling, Pareteum, and FibroGen with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Market Realist•last monthAnalysts Remain Bullish on Intercept Pharmaceuticals
In October, of the 17 analysts covering Intercept Pharmaceuticals (ICPT), eight have given the stock “buy” or higher ratings, and eight have given it “hold” ratings. One analyst has given Intercept a “sell.”
- GlobeNewswire•last month
Astellas Submits New Drug Application in Japan of Roxadustat for The Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff, “FibroGen”) today announced that Astellas submitted a New Drug Application (NDA) for marketing approval in Japan of roxadustat (generic name, development code: ASP1517/FG-4592) for the treatment of anemia associated with Chronic Kidney Disease (CKD) in patients on dialysis. The results obtained from four Phase 3 studies conducted in CKD patients on dialysis in Japan support this NDA submission.
- Simply Wall St.•2 months ago
All You Need To Know About FibroGen Inc’s (NASDAQ:FGEN) Financial Health
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as FibroGen Inc (NASDAQ:FGEN) with a market-capitalization of US$5.08b, rarely draw their attention. While they are less talked Read More...
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Ultragenyx Pharmaceutical and FibroGen
NEW YORK, NY / ACCESSWIRE / September 25, 2018 / U.S. markets closed lower Monday as trade tensions heated up. The Trump administration imposed a tariff of 10 percent on over $200 billion, which could ...
Markit•2 months agoSee what the IHS Markit Score report has to say about FibroGen Inc.
Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding FGEN is favorable, with net inflows of $4.46 billion.
- Reuters•2 months ago
Focus: AstraZeneca plots China robot offensive to counter price cuts
WUXI, China/LONDON (Reuters) - With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China. Tech tie-ups with the likes of Alibaba and Tencent will not directly lift the British group's drug sales, since they are not specific for any one company's products and in many cases will be low-cost or free. "Down the line we benefit, our products benefit, because we have better relationships with doctors and hospital managers and also because we diagnose more patients and they get better treated," Chief Executive Pascal Soriot told Reuters.
Markit•2 months agoSee what the IHS Markit Score report has to say about FibroGen Inc.
Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $751 million over the last one-month into ETFs that hold FGEN are among the lowest of the last year and appear to be slowing.
- Markit•2 months ago
See what the IHS Markit Score report has to say about FibroGen Inc.
Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $1.12 billion over the last one-month into ETFs that hold FGEN are among the lowest of the last year and appear to be slowing.
- GlobeNewswire•2 months ago
FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
FibroGen, Inc. (FGEN), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This follows review of the Phase 2 clinical data evaluating pamrevlumab in a placebo-controlled trial and represents recognition by the FDA that pamrevlumab has the potential to address an unmet medical need for this disease. “This Fast Track designation reflects recognition of the great need for a new therapeutic to help patients diagnosed with IPF to reduce the burden and progression of this debilitating disease and another positive step in developing pamrevlumab for the treatment of IPF,” said Elias Kouchakji, M.D., Senior Vice President, Clinical Development and Drug Safety.
- Reuters•2 months ago
Boost for "made in China" medicine as Chi-Med wins key approval
Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine. The London-listed company - which is known as Chi-Med and is collaborating with Eli Lilly on the drug - said on Wednesday that the National Medical Products Administration of China had approved Elunate or fruquintinib in colorectal cancer.
Markit•3 months agoSee what the IHS Markit Score report has to say about FibroGen Inc.
Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold FGEN had net inflows of $2.95 billion over the last one-month.
